COVID-19 Drug API - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511246876

Publication Date:

November 27, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for COVID-19 Drug API was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for COVID-19 Drug API, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of COVID-19 Drug API by region & country, by Type, and by Application.
The COVID-19 Drug API market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COVID-19 Drug API.
麻豆原创 Segmentation
By Company
Shanghai Zhongxi Sunve Pharma Co., Ltd.
Cinkate
Fuan Pharmaceutical Group
Wuhan Wuyao Pharmaceutical Co., Ltd
Shenhua Pharmaceutical Co., Ltd
Chongqing Kangle Pharmaceutical Co., Ltd.
Segment by Type:
Hydroxychloroquine
Chloroquine Phosphate
Others
Segment by Application
Tablet
Injection
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of COVID-19 Drug API manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of COVID-19 Drug API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of COVID-19 Drug API in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 COVID-19 Drug API Product Introduction
1.2 Global COVID-19 Drug API 麻豆原创 Size Forecast
1.3 COVID-19 Drug API 麻豆原创 Trends & Drivers
1.3.1 COVID-19 Drug API Industry Trends
1.3.2 COVID-19 Drug API 麻豆原创 Drivers & Opportunity
1.3.3 COVID-19 Drug API 麻豆原创 Challenges
1.3.4 COVID-19 Drug API 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global COVID-19 Drug API Players Revenue Ranking (2023)
2.2 Global COVID-19 Drug API Revenue by Company (2019-2024)
2.3 Key Companies COVID-19 Drug API Manufacturing Base Distribution and Headquarters
2.4 Key Companies COVID-19 Drug API Product Offered
2.5 Key Companies Time to Begin Mass Production of COVID-19 Drug API
2.6 COVID-19 Drug API 麻豆原创 Competitive Analysis
2.6.1 COVID-19 Drug API 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by COVID-19 Drug API Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Drug API as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Hydroxychloroquine
3.1.2 Chloroquine Phosphate
3.1.3 Others
3.2 Global COVID-19 Drug API Sales Value by Type
3.2.1 Global COVID-19 Drug API Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global COVID-19 Drug API Sales Value, by Type (2019-2030)
3.2.3 Global COVID-19 Drug API Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Tablet
4.1.2 Injection
4.2 Global COVID-19 Drug API Sales Value by Application
4.2.1 Global COVID-19 Drug API Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global COVID-19 Drug API Sales Value, by Application (2019-2030)
4.2.3 Global COVID-19 Drug API Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global COVID-19 Drug API Sales Value by Region
5.1.1 Global COVID-19 Drug API Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global COVID-19 Drug API Sales Value by Region (2019-2024)
5.1.3 Global COVID-19 Drug API Sales Value by Region (2025-2030)
5.1.4 Global COVID-19 Drug API Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America COVID-19 Drug API Sales Value, 2019-2030
5.2.2 North America COVID-19 Drug API Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe COVID-19 Drug API Sales Value, 2019-2030
5.3.2 Europe COVID-19 Drug API Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific COVID-19 Drug API Sales Value, 2019-2030
5.4.2 Asia Pacific COVID-19 Drug API Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America COVID-19 Drug API Sales Value, 2019-2030
5.5.2 South America COVID-19 Drug API Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa COVID-19 Drug API Sales Value, 2019-2030
5.6.2 Middle East & Africa COVID-19 Drug API Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions COVID-19 Drug API Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions COVID-19 Drug API Sales Value
6.3 United States
6.3.1 United States COVID-19 Drug API Sales Value, 2019-2030
6.3.2 United States COVID-19 Drug API Sales Value by Type (%), 2023 VS 2030
6.3.3 United States COVID-19 Drug API Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe COVID-19 Drug API Sales Value, 2019-2030
6.4.2 Europe COVID-19 Drug API Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe COVID-19 Drug API Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China COVID-19 Drug API Sales Value, 2019-2030
6.5.2 China COVID-19 Drug API Sales Value by Type (%), 2023 VS 2030
6.5.3 China COVID-19 Drug API Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan COVID-19 Drug API Sales Value, 2019-2030
6.6.2 Japan COVID-19 Drug API Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan COVID-19 Drug API Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea COVID-19 Drug API Sales Value, 2019-2030
6.7.2 South Korea COVID-19 Drug API Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea COVID-19 Drug API Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia COVID-19 Drug API Sales Value, 2019-2030
6.8.2 Southeast Asia COVID-19 Drug API Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia COVID-19 Drug API Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India COVID-19 Drug API Sales Value, 2019-2030
6.9.2 India COVID-19 Drug API Sales Value by Type (%), 2023 VS 2030
6.9.3 India COVID-19 Drug API Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Shanghai Zhongxi Sunve Pharma Co., Ltd.
7.1.1 Shanghai Zhongxi Sunve Pharma Co., Ltd. Profile
7.1.2 Shanghai Zhongxi Sunve Pharma Co., Ltd. Main Business
7.1.3 Shanghai Zhongxi Sunve Pharma Co., Ltd. COVID-19 Drug API Products, Services and Solutions
7.1.4 Shanghai Zhongxi Sunve Pharma Co., Ltd. COVID-19 Drug API Revenue (US$ Million) & (2019-2024)
7.1.5 Shanghai Zhongxi Sunve Pharma Co., Ltd. Recent Developments
7.2 Cinkate
7.2.1 Cinkate Profile
7.2.2 Cinkate Main Business
7.2.3 Cinkate COVID-19 Drug API Products, Services and Solutions
7.2.4 Cinkate COVID-19 Drug API Revenue (US$ Million) & (2019-2024)
7.2.5 Cinkate Recent Developments
7.3 Fuan Pharmaceutical Group
7.3.1 Fuan Pharmaceutical Group Profile
7.3.2 Fuan Pharmaceutical Group Main Business
7.3.3 Fuan Pharmaceutical Group COVID-19 Drug API Products, Services and Solutions
7.3.4 Fuan Pharmaceutical Group COVID-19 Drug API Revenue (US$ Million) & (2019-2024)
7.3.5 Wuhan Wuyao Pharmaceutical Co., Ltd Recent Developments
7.4 Wuhan Wuyao Pharmaceutical Co., Ltd
7.4.1 Wuhan Wuyao Pharmaceutical Co., Ltd Profile
7.4.2 Wuhan Wuyao Pharmaceutical Co., Ltd Main Business
7.4.3 Wuhan Wuyao Pharmaceutical Co., Ltd COVID-19 Drug API Products, Services and Solutions
7.4.4 Wuhan Wuyao Pharmaceutical Co., Ltd COVID-19 Drug API Revenue (US$ Million) & (2019-2024)
7.4.5 Wuhan Wuyao Pharmaceutical Co., Ltd Recent Developments
7.5 Shenhua Pharmaceutical Co., Ltd
7.5.1 Shenhua Pharmaceutical Co., Ltd Profile
7.5.2 Shenhua Pharmaceutical Co., Ltd Main Business
7.5.3 Shenhua Pharmaceutical Co., Ltd COVID-19 Drug API Products, Services and Solutions
7.5.4 Shenhua Pharmaceutical Co., Ltd COVID-19 Drug API Revenue (US$ Million) & (2019-2024)
7.5.5 Shenhua Pharmaceutical Co., Ltd Recent Developments
7.6 Chongqing Kangle Pharmaceutical Co., Ltd.
7.6.1 Chongqing Kangle Pharmaceutical Co., Ltd. Profile
7.6.2 Chongqing Kangle Pharmaceutical Co., Ltd. Main Business
7.6.3 Chongqing Kangle Pharmaceutical Co., Ltd. COVID-19 Drug API Products, Services and Solutions
7.6.4 Chongqing Kangle Pharmaceutical Co., Ltd. COVID-19 Drug API Revenue (US$ Million) & (2019-2024)
7.6.5 Chongqing Kangle Pharmaceutical Co., Ltd. Recent Developments
8 Industry Chain Analysis
8.1 COVID-19 Drug API Industrial Chain
8.2 COVID-19 Drug API Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 COVID-19 Drug API Sales Model
8.5.2 Sales Channel
8.5.3 COVID-19 Drug API Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Shanghai Zhongxi Sunve Pharma Co., Ltd.
Cinkate
Fuan Pharmaceutical Group
Wuhan Wuyao Pharmaceutical Co., Ltd
Shenhua Pharmaceutical Co., Ltd
Chongqing Kangle Pharmaceutical Co., Ltd.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.